EGFR and neoplasm: Almost half of the patients carry EGFR-driven tumor with phosphatase and tensin homolog (PTEN) deletion, which are resistant to EGFR target therapy, implying PTEN deficiency plays an important role in resistance to anti-EGFR therapy (Mellinghoff et al., 2007; Arif et al., 2018; Brito et al., 2019).